The development of novel agents for the treatment of colorectal cancer: A critical review of current practice and some suggestions for the future

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 3, 2007, Pages 167-172

  Marshall, John L ^a   Gehan, Edmund A ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Department of Biostatistics Bioinformatics and Biomathematics ^*

Author keywords

Clinical trial design; Colorectal cancer; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST METASTASIS; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION PROFILING; HUMAN; NEUROTOXICITY; REPEATED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG DESIGN; FORECASTING; HUMANS; RESEARCH;

EID: 34247491584     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Yu-Ning Wong Y, Meropol NJ, Sargent D, Goldberg R, Beck JR. Direct cost survival analysis of treatment of metastatic colorectal cancer. J Clin Oncol. 2006;25(18S pt 1): Abstract 3515.
2. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous FOLFIRI in advanced colorectal cancer: a randomized GISCAD trial. J Clin Oncol. 2006;25(18S pt 1): Abstract 3505.
3. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study. J Clin Oncol. 2006;25(18S pt 1): Abstract 3504.
4. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
5. Thall PF, Simon R, Estey E. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995;14:357-379.
6. Thall PF, Simon R. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol. 1996;14:296-303.
7. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Res. 2004; 10:6759-6763.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
9. Friedlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005;11:7872-7878.